Top

Published in:

10-08-2022 | Addiction

Economic Evaluation Design within the HEAL Prevention Cooperative

Authors: Laura J. Dunlap, Margaret R. Kuklinski, Alexander Cowell, Kathryn E. McCollister, Diana M. Bowser, Mark Campbell, Claudia-Santi F. Fernandes, Pranav Kemburu, Bethany J. Livingston, Lisa A. Prosser, Vinod Rao, Rosanna Smart, Tansel Yilmazer

Published in: Prevention Science | Special Issue 1/2023

Abstract

The rapid rise in opioid misuse, disorder, and opioid-involved deaths among older adolescents and young adults is an urgent public health problem. Prevention is a vital part of the nation’s response to the opioid crisis, yet preventive interventions for those at risk for opioid misuse and opioid use disorder are scarce. In 2019, the National Institutes of Health (NIH) launched the Preventing Opioid Use Disorder in Older Adolescents and Young Adults cooperative as part of its broader Helping to End Addiction Long-term (HEAL) Initiative (https://heal.nih.gov/). The HEAL Prevention Cooperative (HPC) includes ten research projects funded with the goal of developing effective prevention interventions across various settings (e.g., community, health care, juvenile justice, school) for older adolescent and young adults at risk for opioid misuse and opioid use disorder (OUD). An important component of the HPC is the inclusion of an economic evaluation by nine of these research projects that will provide information on the costs, cost-effectiveness, and sustainability of these interventions. The HPC economic evaluation is integrated into each research project’s overall design with start-up costs and ongoing delivery costs collected prospectively using an activity-based costing approach. The primary objectives of the economic evaluation are to estimate the intervention implementation costs to providers, estimate the cost-effectiveness of each intervention for reducing opioid misuse initiation and escalation among youth, and use simulation modeling to estimate the budget impact of broader implementation of the interventions within the various settings over multiple years. The HPC offers an extraordinary opportunity to generate economic evidence for substance use prevention programming, providing policy makers and providers with critical information on the investments needed to start-up prevention interventions, as well as the cost-effectiveness of these interventions relative to alternatives. These data will help demonstrate the valuable role that prevention can play in combating the opioid crisis.

Available only for authorised users

Acharya, M., Chopra., D., Hayes, C. J., Teeter, B., & Martin, B. C. (2020). Cost-effectiveness of intranasal naloxone distribution to high-risk prescription opioid users. Value in Health, 23(4), 451–460. (ISSN 1098–3015). https://doi.org/10.1016/j.jval.2019.12.002

Banerjee, S., & Wright, M. D. (2020). Injectable opioid agonist treatment for patients with opioid dependence: a review of clinical and cost-effectiveness. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. Available from: https://www.ncbi.nlm.nih.gov/books/NBK564232/

Barnett, T. E., Thompson, E. L., Litt, D. M., & Lewis, M. A. (2019). Correlates of nonmedical prescription opioid use among U.S. adolescents. American Journal of Preventive Medicine, 57(5), e175–e179. https://doi.org/10.1016/j.amepre.2019.05.006

Bjornestad, J., McKay, J. R., Berg, H., Moltu, C., & Nesvåg, S. (2020). How often are outcomes other than change in substance use measured? A systematic review of outcome measures in contemporary randomised controlled trials. Drug and Alcohol Review, 39, 394–414. https://doi.org/10.1111/dar.13051. Epub 2020 Mar 9 PMID: 32147903.CrossRefPubMed

Bonar, E. E., Coughlin, L., Roche, J. S., Philyaw-Kotov, M. L., Bixler, E. A., Sinelnikov, S., Kolosh, A., Cihak, M. J., Cunningham, R. M., & Walton, M. A. (2020). Prescription opioid misuse among adolescents and emerging adults in the United States: A scoping review. Preventive Medicine, 132, 105972. https://doi.org/10.1016/j.ypmed.2019.105972CrossRefPubMedPubMedCentral

Boyd, C. J., Young, A., & McCabe, S. E. (2014). Psychological and drug abuse symptoms associated with nonmedical use of opioid analgesics among adolescents. Substance Abuse, 35, 284–289. https://doi.org/10.1080/08897077.2014.928660CrossRefPubMed

Busch, S. H., Fiellin, D. A., Chawarski, M. C., Owens, P. H., Pantalon, M. V., Hawk, K., Bernstein, S. L., O’Connor, P. G., & D’Onofrio, G. (2017). Cost-effectiveness of emergency department-initiated treatment for opioid dependence. Addiction (abingdon, England), 112, 2002–2010. https://doi.org/10.1111/add.13900CrossRefPubMed

Catalano, R. F., White, H. R., Fleming, C. B., & Haggerty, K. P. (2011). Is nonmedical prescription opiate use a unique form of illicit drug use? Addictive Behaviors, 36, 79–86. https://doi.org/10.1016/j.addbeh.2010.08.028CrossRefPubMedPubMedCentral

Caulkins, J. P., Rydell, C. P., Everingham, S. S., Chiesa, J., & Bushway, S. (1999). An ounce of prevention, a pound of uncertainty: The cost-effectiveness of school-based drug prevention programs. RAND Corporation. https://doi.org/10.7249/MR923CrossRef

Cerdá, M., Santaella, J., Marshall, B. D., Kim, J. H., & Martins, S. S. (2015). Nonmedical prescription opioid use in childhood and early adolescence predicts transitions to heroin use in young adulthood: A national study. Journal of Pediatrics, 167, 605–612. https://doi.org/10.1016/j.jpeds.2015.04.071CrossRefPubMed

Compton, W. M., Jones, C. M., Baldwin, G. T., Harding, F. M., Blanco, C., & Wargo, E. M. (2019). Targeting youth to prevent later substance use disorder: An underutilized response to the US opioid crisis. American Journal of Public Health, 109, S185–S189. https://doi.org/10.2105/AJPH.2019.305020CrossRefPubMedPubMedCentral

Corso, P. S., Visser, S. N., Ingels, J. B., & Perou, R. (2015). Cost-effectiveness of Legacy for Children™ for reducing behavioral problems and risk for ADHD among children living in poverty. Journal of Child and Adolescent Behavior, 3, 240. https://doi.org/10.4172/2375-4494.1000240CrossRefPubMedPubMedCentral

Crowley, D. M., Jones, D. E., Coffman, D. L., & Greenberg, M. T. (2014). Can we build an efficient response to the prescription drug abuse epidemic? Assessing the cost effectiveness of universal prevention in the PROSPER trial. Preventive Medicine, 62, 71–77. https://doi.org/10.1016/j.ypmed.2014.01.029CrossRefPubMedPubMedCentral

Crowley, D. M., Dodge, K. A., Barnett, W. S., Corso, P., Duffy, S., Graham, P., & Plotnick, R. (2018). Standards of evidence for conducting and reporting economic evaluations in prevention science. Prevention Science, 19, 366–390.CrossRefPubMedPubMedCentral

Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G.W. (2015). Methods for the economic evaluation of health care programmes (4th., ed). Oxford: Oxford University Press. https://books.google.co.uk/books?id=lvWACgAAQBAJ

Dunlap, L. J., Orme, S., Zarkin, G. A., Arias, S. A., Miller, I. W., Camargo, C. A., Jr., Sullivan, A. F., Allen, M. H., Goldstein, A. B., Manton, A. P., Clark, R., & Boudreaux, E. D. (2019). Screening and intervention for suicide prevention: A cost-effectiveness analysis of the ED-SAFE interventions. Psychiatric. Services, 70, 1082–1087. https://doi.org/10.1176/appi.ps.201800445CrossRefPubMed

Edlund, M. J., Forman-Hoffman, V. L., Winder, C. R., Heller, D. C., Kroutil, L. A., Lipari, R. N., & Colpe, L. J. (2015). Opioid abuse and depression in adolescents: Results from the National Survey on Drug Use and Health. Drug and Alcohol Dependence, 152, 131–138. https://doi.org/10.1016/j.drugalcdep.2015.04.010CrossRefPubMed

Fenwick, E., Claxton, K., & Sculpher, M. (2001). Representing uncertainty: The role of cost-effectiveness acceptability curves. Health Economics, 10, 779–787. https://doi.org/10.1002/hec.635CrossRefPubMed

Fenwick, E., Marshall, D. A., Levy, A. R., & Nichol, G. (2006). Using and interpreting cost-effectiveness acceptability curves: An example using data from a trial of management strategies for atrial fibrillation. BMC Health Services Research, 6, 52. https://doi.org/10.1186/1472-6963-6-52CrossRefPubMedPubMedCentral

Gomes, T., Tadrous, M., Mamdani, M. M., Paterson, J. M., & Juurlink, D. N. (2018). The burden of opioid-related mortality in the United States. JAMA Network Open, 1, e180217–e180217.CrossRefPubMedPubMedCentral

Groenewald, C. B., Patel, K. V., Rabbitts, J. A., & Palermo, T. M. (2020). Correlates and motivations of prescription opioid use among adolescents 12 to 17 years of age in the United States. Pain, 161, 742–748. https://doi.org/10.1097/j.pain.0000000000001775CrossRefPubMedPubMedCentral

Hollands, F., Bowden, A. B., Belfield, C., Levin, H. M., Cheng, H., Shand, R., Pan, R., & Hanisch-Cerda, B. (2014). Cost-effectiveness analysis in practice: Interventions to improve high school completion. Educational Evaluation and Policy Analysis, 36, 307–326. https://doi.org/10.3102/0162373713511850CrossRef

Hu, M. C., Griesler, P., Wall, M., & Kandel, D. B. (2017). Age-related patterns in nonmedical prescription opioid use and disorder in the US population at ages 12–34 from 2002 to 2014. Drug and Alcohol Dependence, 177, 237–243. https://doi.org/10.1016/j.drugalcdep.2017.03.024CrossRefPubMedPubMedCentral

Ingels, J. B., Corso, P. S., Kogan, S. M., & Brody, G. H. (2013). Cost-effectiveness of the strong African American families-teen program: 1-year follow-up. Drug and Alcohol Dependence, 133, 556–561. https://doi.org/10.1016/j.drugalcdep.2013.07.036CrossRefPubMed

Jensen, P. S., Garcia, J. A., Glied, S., Crowe, M., Foster, M., Schlander, M., Hinshaw, S., Vitiello, B., Arnold, L. E., Elliott, G., Hechtman, L., Newcorn, J. H., Pelham, W. E., Swanson, J., & Wells, K. (2005). Cost-effectiveness of ADHD treatments: Findings from the multimodal treatment study of children with ADHD. American Journal of Psychiatry, 162, 1628–1636. https://doi.org/10.1176/appi.ajp.162.9.1628CrossRefPubMed

Martins, S. S., Kim, J. H., Chen, L. -Y., Levin, D., Keyes, K. M., Cerdáa, M., & Storr, C. L. (2015). Nonmedical prescription drug use among US young adults by educational attainment. Social. Psychiatry and Psychiatric. Epidemiology, 50, 713–724. https://doi.org/10.1007/s00127-014-0980-3CrossRefPubMed

Martins, S. S., Segura, L. E., Santaella Tenorio, J., Perlmutter, A. S., Fenton, M. C., Cerdá, M., Keyes, K. M., Ghandour, L. A., Storr, C. L., & Hasin, D. S. (2017). Prescription opioid use disorder and heroin use among 12–34 year-olds in the United States from 2002 to 2014. Addictive Behaviors, 65, 236–241. https://doi.org/10.1016/j.addbeh.2016.08.033CrossRefPubMed

Mauskopf, J. A., Sullivan, S. D., Annemans, L., Caro, J., Mullins, C. D., Nuijten, M., Orleewska, E., Watkins, J., & Trueman, P. (2007). Principles of good practice for budget impact analysis: Report of the ISPOR Task Force on good research practices—budget impact analysis. Value Health, 10, 336–347. https://doi.org/10.1111/j.1524-4733.2007.00187.xCrossRefPubMed

Murphy, S. M., McCollister, K. E., Leff, J. A., Yang, X., Jeng, P. J., Lee, J. D., Nunes, E. V., Novo, P., Rotrosen, J., & Schackman, B. R. (2019). Cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone to prevent opioid relapse. Annals of Internal Medicine, 170, 90–98. https://doi.org/10.7326/M18-0227CrossRefPubMed

Neumann, P. J., Sanders, G. D., Russell, L. B., Siegel, J. E., & Ganiats, T. G. (2016). Cost- effectiveness in health and medicine. CrossRef

Ridenour, T. A., Cruden, R., Yang, Y., Bonar, E., Rodriguez, A., Saavedra, L., Hussong, A., Walton, M., Deeds, B., Ford, J., Knight, D., Haggerty, K., Stormshak, E., Kominsky, T., Aherns, K., Woodward, D., Feng, X., Fiellin, L., Wilens, T., Klein, D., & Fernandes, C. S. (2022; Under review). Methodological strategies for prospective harmonization of studies: Application to the HEAL Prevention Cooperative.

Sanders, G. D., Neumann, P. J., Basu, A., Brock, D. W., Feeny, D., Krahn, M., Kuntz, K. M., Meltzer, D. O., Owens, D. K., Prosser, L. A., Salomon, J. A., Sculpher, M. J., Trikalinos, T. A., Russell, L. B., Siegel, J. E., & Ganiats, T. G. (2016). Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second panel on cost-effectiveness in health and medicine. JAMA, 316, 1093–1103. https://doi.org/10.1001/jama.2016.12195CrossRefPubMed

Schepis, T. S., & Hakes, J. K. (2017). Age of initiation, psychopathology, and other substance use are associated with time to use disorder diagnosis in persons using opioids nonmedically. Substance Abuse, 38, 407–413. https://doi.org/10.1080/08897077.2017.1356791CrossRefPubMed

Schepis, T. S., Klare, D. L., Ford, J. A., & McCabe, S. E. (2020). Prescription drug misuse: Taking a lifespan perspective. Substance Abuse: Research and Treatment, 14, 1178221820909352. https://doi.org/10.1177/1178221820909352CrossRefPubMed

Spoth, R., Trudeau, L., Shin, C., Ralston, E., Redmond, C., Greenberg, M., & Feinberg, M. (2013). Longitudinal effects of universal preventive intervention on prescription drug misuse: Three randomized controlled trials with late adolescents and young adults. American Journal of Public Health, 103(4), 665–672. https://doi.org/10.2105/AJPH.2012.301209

Steuerle, E., Jackson, L. M., Committee on the Use of Economic Evidence to Inform Investments in Children, Youth, and Families, Board on Children, Youth, and Families, Division of Behavioral and Social Sciences and Education, & National Academies of Sciences, Engineering, and Medicine (Eds.). (2016). Advancing the power of economic evidence to inform investments in children, youth, and families. Washington, DC: The National Academies Press. https://doi.org/10.17226/23481

Substance Abuse and Mental Health Services Administration, Office of the Surgeon General. (2016, November). Facing addiction in America: The Surgeon General’s Report on alcohol, drugs, and health. Washington, DC: U.S. Department of Health and Human Services, Reports of the Surgeon General. PMID: 28252892.

U.S. Bureau of Labor Statistics. (2021). Occupational employment statistics: May 2019 National Occupational Employment and Wage Estimates United States. https://www.bls.gov/oes/current/oes_nat.html

U.S. Department of Labor. (2021). O*Net Online. https://www.onetonline.org/

U.S. Department of Labor Statistics. (2022). Employer costs for employee compensation for the regions – December 2021. https://www.bls.gov/regions/southwest/news-release/pdf/employercostsforemployeecompensation_regions.pdf

Volkow, N. D., Jones, E. B., Einstein, E. B., & Wargo, E. M. (2019). Prevention and treatment of opioid misuse and addiction: A review. JAMA Psychiatry, 76, 208–216. https://doi.org/10.1001/jamapsychiatry.2018.3126CrossRefPubMed

Wichmann, A. B., Adang, E. M., Stalmeier, P. F., Kristanti, S., Van den Block, L., Vernooij-Dassen, M. J., Engels, Y., & PACE. (2017). The use of quality-adjusted life years in cost-effectiveness analyses in palliative care: Mapping the debate through an integrative review. Palliative Medicine, 31, 306–322. https://doi.org/10.1177/0269216316689652CrossRefPubMed

Zullig, K. J., & Divin, A. L. (2012). The association between non-medical prescription drug use, depressive symptoms, and suicidality among college students. Addictive Behaviors, 37, 890–899. https://doi.org/10.1016/j.addbeh.2012.02.008CrossRefPubMed

Title: Economic Evaluation Design within the HEAL Prevention Cooperative
Authors: Laura J. Dunlap
Margaret R. Kuklinski
Alexander Cowell
Kathryn E. McCollister
Diana M. Bowser
Mark Campbell
Claudia-Santi F. Fernandes
Pranav Kemburu
Bethany J. Livingston
Lisa A. Prosser
Vinod Rao
Rosanna Smart
Tansel Yilmazer
Publication date: 10-08-2022
Publisher: Springer US
Keywords: Addiction
Opioids
Opioids
Addiction
Published in: Prevention Science / Issue Special Issue 1/2023
Print ISSN: 1389-4986
Electronic ISSN: 1573-6695
DOI: https://doi.org/10.1007/s11121-022-01400-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Economic Evaluation Design within the HEAL Prevention Cooperative

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2023

Accelerating Solutions for the Overdose Crisis: an Effectiveness-Implementation Hybrid Protocol for the HEAL Prevention Cooperative

Strengthening Prevention Systems to Address the Overdose Crisis Through the HEAL Prevention Cooperative and HEAL Preventing Opioid Use Disorder Research Program

Commentary: Improving the Effectiveness and Utility of the Helping to End Addiction Long-Term (HEAL) Prevention Cooperative: A Full Translational Framework

Including Community Partners in the Development and Adaptation of Intervention Strategies to Prevent Initiation or Escalation of Opioid Misuse

Prevention of Opioid Use and Disorder Among Youth Involved in the Legal System: Innovation and Implementation of Four Studies Funded by the NIDA HEAL Initiative

Culturally Responsive Opioid and Other Drug Prevention for American Indian/Alaska Native People: a Comparison of Reservation- and Urban-Based Approaches